Fludarabine
Hematopoietic Cell Transplant Recipient
Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Hematopoietic Cell Transplant Recipient cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 2 | B |
FILGRASTIM Fred Hutchinson Cancer Center | Phase 2 | CCC |
TACROLIMUS Fred Hutchinson Cancer Center | Phase 2 | CCC |
Monomethyl Fumarate Fred Hutchinson Cancer Center | Phase 2 | CCC |
wt1-sensitized allogeneic t-lymphocytes Fred Hutchinson Cancer Center | Phase 1/2 | CCC |
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine City of Hope Medical Center | Phase 1 | CC |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →